Tourmaline Bio, Inc., a Novartis Company
Clinical trials sponsored by Tourmaline Bio, Inc., a Novartis Company, explained in plain language.
A biotech company, now part of Novartis, developing immunotherapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection every 8 weeks shows promise for thyroid eye disease Results expected Sep 2026 (estimated)